Cipla, the market leader in respiratory therapies, expects a surge in demand for respiratory drugs and inhalers during the coming months when the winter and an anticipated second Covid wave are likely to push up demand for these medicines.
The firm enjoys a massive 68.7 per cent market share in the respiratory inhalation segment in India and has started working on aligning supplies so that there is no shortage of these critical medicines.
During this time, pollution levels (especially in north India) and other environmental factors cause a surge in respiratory illnesses. Cipla aspires to become the global lungs leader and it currently ranks second in the world.
People, who are recovering from Covid-19, are also suffering from lung damage and other respiratory illnesses as an after-effect of the…
